[Skip to Navigation]
August 1969

Immunization With Live Attenuated Rubella Virus Vaccine (HPV-77): Clinical and Serological Results in Children and Adolescents in Israel

Author Affiliations

Jerusalem, Israel; Ness-Ziona, Israel
From the Department of Virology, Hebrew University-Hadassah Medical School (Dr. Goldblum), and the Division of Epidemiology, Ministry of Health (Dr. Swartz), Jerusalem, Israel; and the departments of virology (Drs. W. Klingberg and Goldwasser) and epidemiology (Dr. M. Klingberg), Israel Institute for Biological Research, Ness-Ziona, Israel.

Am J Dis Child. 1969;118(2):190-196. doi:10.1001/archpedi.1969.02100040192006

THE experience with live attenuated rubella virus vaccines which has accumulated in the last few years shows a clear need for a rubella vaccine that is not only safe and effective, but also has few or no side affects when recommended as a routine procedure. Age seems to affect the intensity of the clinical response to vaccine administration, and, since joint manifestations have been reported in adult women immunized with rubella vaccine,1-3 it was considered desirable to study the age effect further by investigating the clinical and serological reactions in a broad age spectrum of susceptible women.

For this purpose a field trial was initiated in Israel during the autumn and winter months of 1968 and 1969 which included a representative number of female subjects of various ages. The preliminary observations of the trial are presented in this report.

Materials and Methods  Study Group.—This group included 239 girls,